Chimeric autoantibody receptor T cells enter pemphigus vulgaris
Desmoglein 3-targeted CAART cell therapy programs in pemphigus vulgaris are reading out as a precision approach to autoantibody-driven disease.
Pemphigus vulgaris has been a corticosteroid, rituximab, and immunosuppressant category. Chimeric autoantibody receptor T cell (CAART) programs targeting desmoglein-3-specific B cells (the cells that produce the disease-driving autoantibodies) are reaching pivotal data. The proposition is precision elimination of just the disease-driving B cells rather than broad B-cell depletion. The commercial economics are demanding (one-time complex therapy) but the precision proposition reframes autoantibody-driven autoimmune commercial planning if it holds.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.